Search research articles
Contact Us
Filters
Showing results (121-130 of 134) with videos related to
Page
of 14
Sort By:
Journal of the National Cancer Institute
|
April 14, 2016
Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers
Gloria Y F Ho, Siqun L Zheng, Mary Cushman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2005
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma
Charles Lu, Roman Perez-Soler, Bilal Piperdi, et al.
Clinical Lung Cancer
|
December 7, 2016
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer
Tianhong Li, Bilal Piperdi, William V Walsh, et al.
Cancer Discovery
|
May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
Thomas J Lynch, Philip D Bonomi, Charles Butts, et al.
Cancer Cell
|
June 16, 2021
Seroconversion rates following COVID-19 vaccination among patients with cancer
Astha Thakkar, Jesus D Gonzalez-Lugo, Niyati Goradia, et al.
Gut
|
May 17, 2022
Hepatic p63 regulates glucose metabolism by repressing SIRT1
Maria J Gonzalez-Rellan, Eva Novoa, Natalia da Silva Lima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
Novel agents in the treatment of lung cancer: conference summary statement
Thomas J Lynch, Alex A Adjei, Paul A Bunn, et al.
Cancer Discovery
|
September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
Haiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.
The Lancet. Oncology
|
November 14, 2017
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Heather A Wakelee, Suzanne E Dahlberg, Steven M Keller, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 134) with videos related to
Sort By:
Page
of 14
Journal of the National Cancer Institute
|
April 14, 2016
Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers
Gloria Y F Ho, Siqun L Zheng, Mary Cushman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2005
Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma
Charles Lu, Roman Perez-Soler, Bilal Piperdi, et al.
Clinical Lung Cancer
|
December 7, 2016
Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer
Tianhong Li, Bilal Piperdi, William V Walsh, et al.
Cancer Discovery
|
May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
Thomas J Lynch, Philip D Bonomi, Charles Butts, et al.
Cancer Cell
|
June 16, 2021
Seroconversion rates following COVID-19 vaccination among patients with cancer
Astha Thakkar, Jesus D Gonzalez-Lugo, Niyati Goradia, et al.
Gut
|
May 17, 2022
Hepatic p63 regulates glucose metabolism by repressing SIRT1
Maria J Gonzalez-Rellan, Eva Novoa, Natalia da Silva Lima, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
Novel agents in the treatment of lung cancer: conference summary statement
Thomas J Lynch, Alex A Adjei, Paul A Bunn, et al.
Cancer Discovery
|
September 16, 2015
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
Haiying Cheng, Yiyu Zou, Jeffrey S Ross, et al.
The Lancet. Oncology
|
November 14, 2017
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Heather A Wakelee, Suzanne E Dahlberg, Steven M Keller, et al.
Page
of 14